Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director Ali Behbahani sold 13,679 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the transaction, the director directly owned 16,637 shares in the company, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CRISPR Therapeutics Stock Up 3.1%

Shares of CRISPR Therapeutics stock traded up $1.77 on Monday, reaching $58.33. 1,813,544 shares of the company were exchanged, compared to its average volume of 1,761,454. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.76. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The company has a 50-day moving average of $53.08 and a 200 day moving average of $52.77.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -4.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRSP. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday, August 25th. HC Wainwright reissued a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, August 31st. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $67.94.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank bought a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $25,706,000. Canal Insurance CO bought a new stake in CRISPR Therapeutics in the 1st quarter valued at $1,670,000. Quantinno Capital Management LP grew its holdings in CRISPR Therapeutics by 613.5% in the 1st quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock valued at $2,283,000 after buying an additional 41,263 shares in the last quarter. Blue Jean Financial LLC acquired a new position in CRISPR Therapeutics in the 4th quarter valued at $1,470,000. Finally, KBC Group NV increased its position in CRISPR Therapeutics by 3,999.9% during the 1st quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after buying an additional 113,997 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.